Clinitech Lab

Why is Clinitech Laboratory Ltd falling/rising?

As of 31-Aug, Clinitech Laboratory Ltd's stock price is stable at Rs 36.60, with a recent short-term rise of 3.10% but a significant long-term decline of 30.29% over the past year, indicating underlying challenges despite current stability.

As of 31-Aug, Clinitech Laboratory Ltd's stock price is currently stable at Rs 36.60, showing no change (0.00%). However, the stock has experienced a mixed performance over different periods. In the past week, it has risen by 3.10%, outperforming the Sensex, which fell by 0.53%. This indicates a short-term positive trend. <BR><BR>Despite this recent uptick, the stock has seen a significant decline over the longer term, with a decrease of 8.50% over the past month and a substantial drop of 30.29% over the past year. Additionally, the stock has been trading lower than its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, suggesting a longer-term bearish trend.<BR><BR>Today's trading activity shows that Clinitech Laboratory Ltd opened with a gain of 4.57% and reached an intraday high of Rs 36.60, but it has not fluctuated from this price since opening. The stock's erratic trading pattern, with no trades on 2 out of the last 20 days, may also contribute to its volatility. Overall, while there is a short-term rise, the longer-term performance and trading patterns indicate underlying challenges for the stock.

What does Clinitech Lab do?

Clinitech Laboratory Ltd is a micro-cap company in the healthcare services industry, incorporated in 2010 and publicly listed since August 2023. It has a market cap of INR 8 Cr, with a P/E ratio of 20.00 and a return on equity of 4.54%.

Overview:<BR>Clinitech Laboratory Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Clinitech Laboratory Limited was incorporated as Clinitech Laboratory Private Limited in 2010. The company changed its status to Public Limited and adopted its current name on August 25, 2023.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 8 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 20.00<BR>Industry P/E: N/A<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.18<BR>Return on Equity: 4.54%<BR>Price-to-Book: 0.86<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Clinitech Lab?

Clinitech Lab's peers include Samsrita Labs, Transgene Biotek, Vanta Bioscience, Dhanvantri Jeev., Family Care, Looks Health, Ashram Online, Dr Lalchand. Lab, and Gian Lifecare. Dhanvantri Jeev. shows the highest 1-year return at 26.19%, while Gian Lifecare has the lowest at -67.47%, with Clinitech Lab at -30.29%.

Peers: The peers of Clinitech Lab are Samsrita Labs, Transgene Biotek, Vanta Bioscience, Dhanvantri Jeev., Family Care, Looks Health, Ashram Online, Dr Lalchand. Lab, and Gian Lifecare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Family Care, while Average management risk is found at Dhanvantri Jeev. and Dr Lalchand. Lab, and the rest have Below Average or do not qualify. Good growth is seen at Family Care, while Below Average growth is noted at Dhanvantri Jeev., Clinitech Lab, Vanta Bioscience, and the rest. Good capital structure is present at Dhanvantri Jeev., Clinitech Lab, Dr Lalchand. Lab, Gian Lifecare, while the rest do not qualify or have Below Average ratings.<BR><BR>Return Snapshot: Dhanvantri Jeev. has the highest 1-year return at 26.19%, while Gian Lifecare has the lowest at -67.47%. Clinitech Lab's 1-year return of -30.29% is better than Gian Lifecare's but worse than Dhanvantri Jeev. Additionally, several peers, including Family Care, Dr Lalchand. Lab, and Gian Lifecare, have negative six-month returns.

Which are the latest news on Clinitech Lab?

How big is Clinitech Lab?

As of 10th June, Clinitech Laboratory Ltd has a market capitalization of 9.00 Cr, classified as a Micro Cap, with Shareholder's Funds of 8.83 Cr and Total Assets of 10.55 Cr reported as of March 2025. There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Clinitech Laboratory Ltd has a market capitalization of 9.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 8.83 Cr and Total Assets valued at 10.55 Cr.

How has been the historical performance of Clinitech Lab?

Clinitech Lab's historical performance shows increasing net sales and total assets, but declining profitability metrics such as operating profit and net income over the past three years. Despite challenges in cash flow management, the company reported a net cash inflow of 2.00 Cr in Mar'25.

Answer:<BR>The historical performance of Clinitech Lab shows a mixed trend in financial metrics over the past three years.<BR><BR>Breakdown:<BR>Clinitech Lab's net sales increased from 6.35 Cr in Mar'23 to 6.40 Cr in Mar'24, and further to 8.23 Cr in Mar'25, indicating a positive growth trajectory. Total operating income followed a similar pattern, reaching 8.23 Cr in Mar'25. However, total expenditure also rose significantly from 4.99 Cr in Mar'23 to 7.40 Cr in Mar'25, leading to a decline in operating profit (PBDIT) from 1.36 Cr in Mar'23 to 1.06 Cr in Mar'25. Profit before tax showed a decrease from 0.86 Cr in Mar'23 to 0.55 Cr in Mar'25, while profit after tax also fell from 0.61 Cr in Mar'23 to 0.39 Cr in Mar'25. Despite these declines, earnings per share (EPS) decreased from 4.07 in Mar'23 to 1.71 in Mar'25. On the balance sheet, total assets grew from 5.88 Cr in Mar'23 to 10.55 Cr in Mar'25, with total liabilities increasing from 5.88 Cr to 10.55 Cr in the same period. The company reported a net cash inflow of 2.00 Cr in Mar'25, contrasting with previous years where cash flow from operating activities was negative. Overall, Clinitech Lab's financial performance reflects growth in sales and assets but challenges in profitability and cash flow management.

When is the next results date for Clinitech Lab?

The next results date for Clinitech Lab is 12 November 2025.

The next results date for Clinitech Lab is scheduled for 12 November 2025.

Is Clinitech Lab overvalued or undervalued?

As of August 28, 2025, Clinitech Lab is considered undervalued with a PE ratio of 11.41 and a low PEG ratio of 0.00, indicating a positive shift in its valuation grade to attractive, despite a year-to-date return of -36.6%, while outperforming the Sensex over the past month.

As of 28 August 2025, Clinitech Lab's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 11.41, an EV to EBITDA ratio of 11.57, and a ROE of 10.99%. These metrics suggest that Clinitech Lab offers a compelling investment opportunity compared to its peers.<BR><BR>In the peer comparison, Clinitech Lab's PE ratio of 11.41 stands in stark contrast to Max Healthcare's exorbitant 93.61 and Apollo Hospitals' 70.56, both of which are categorized as very expensive. Additionally, Clinitech's PEG ratio is notably low at 0.00, further supporting the undervaluation narrative. While the stock has faced challenges with a year-to-date return of -36.6%, it has outperformed the Sensex over the past month, which saw a decline of 1.00%. This performance may indicate a potential recovery and growth trajectory for Clinitech Lab.

Who are the top shareholders of the Clinitech Lab?

The top shareholders of Clinitech Lab include promoter Jyoti Jagdish Nayak with 29.57%, public shareholder Santosh Gopalkrishna Kudva with 6.2%, and individual investors collectively owning 36.28%. There is one foreign institutional investor holding 0.32%, and no mutual funds are currently invested in the company.

The top shareholders of Clinitech Lab include the promoters, who hold the majority of the shares. The promoter with the highest holding is Jyoti Jagdish Nayak, who owns 29.57% of the company. Additionally, the highest public shareholder is Santosh Gopalkrishna Kudva, holding 6.2%. Individual investors collectively own 36.28% of the shares, while there is one foreign institutional investor (FII) that holds 0.32%. There are currently no mutual funds holding shares in the company.

What is the technical trend for Clinitech Lab?

As of June 5, 2025, Clinitech Lab's trend is bearish with moderate strength, supported by bearish signals from Bollinger Bands and moving averages, despite a mildly bullish weekly MACD and some divergence in the OBV.

As of 5 June 2025, the technical trend for Clinitech Lab has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD indicates a mildly bullish signal, but this is overshadowed by bearish signals from the Bollinger Bands and moving averages on the daily timeframe. Additionally, both the weekly and monthly Dow Theory confirm a bearish outlook. The OBV shows a mildly bearish trend on the weekly, while the monthly is mildly bullish, suggesting some divergence. Overall, the negative performance over the past week and month further supports the bearish sentiment.

Has Clinitech Lab declared dividend?

No Dividend History Available